Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Quest Research Institute

Neither a doctor nor a teaching hospital

Research payments

$3,949,559

463 payments

Through program year 2025, Quest Research Institute is reported as receiving $3,949,559 in research payments, across 463 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $972,872 200
2024 Research $370,330 61
2023 Research $648,490 18
2022 Research $281,567 19
2021 Research $371,392 32
2020 Research $145,140 36
2019 Research $1,159,768 97

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $819,785 2 payments
  2. Eli Lilly and Company $579,592 12 payments
  3. Ucb SA $483,703 24 payments
  4. Seqirus USA Inc $369,969 159 payments
  5. AstraZeneca UK Limited $366,986 2 payments
  6. Vertex Pharmaceuticals Incorporated $344,990 7 payments
  7. Eisai Inc. $242,585 118 payments
  8. AstraZeneca Pharmaceuticals LP $223,021 3 payments
  9. Sage Therapeutics, Inc. $208,465 10 payments
  10. Roche TCRC, Inc. $118,460 9 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized Double Blind Placebo Controlled Parallel Group Study to Evaluate the Efficacy of Two Doses of Cnp520 in Participants at Risk for the Onset of Clinical Symptoms of Ad $819,785 2 payments
  2. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $373,132 4 payments
  3. A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment $366,986 2 payments
  4. A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age $361,797 155 payments
  5. A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of Oral VX-993 in Subjects With Pain Associated With Diabetic Peripheral Neuropathy $289,906 2 payments
  6. A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ucb0599 in Study Participants With Early Parkinsons Disease $180,231 12 payments
  7. A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $169,679 109 payments
  8. A Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Ucb0599 in Patients With Parkinson?S Disease (PD) $167,928 1 payment
  9. A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $130,640 1 payment
  10. A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Participants living with Obesity or Overweight with Comorbidity $130,548 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record